Statin use found beneficial in hepatitis C treatment

Statin use found beneficial in hepatitis C treatment

(HealthDay)—For patients with hepatitis C virus (HCV), statin therapy is associated with improved virologic response rates, as well as decreased liver fibrosis progression and hepatocellular carcinoma (HCC) incidence, according to a study published online April 6 in Hepatology.

Adeel A. Butt, M.D., from the VA Pittsburgh Healthcare System, and colleagues examined the impact of adding statins to antiviral therapy upon sustained virologic response (SVR) rates, fibrosis progression, and HCC development among HCV infected persons. Data were collected from 7,248 eligible subjects from the Electronically Retrieved Cohort of HCV Infected Veterans, of whom 46 percent received statins.

The researchers observed significant correlations for statin use with attaining SVR (39.2 versus 33.3 percent; P < 0.01), decreased development of cirrhosis (17.3 versus 25.2 percent; P < 0.001), and decreased incident HCC (1.2 versus 2.6 percent; P < 0.01). After adjustment for other relevant clinical factors, statins remained significantly associated with increased odds of SVR (odds ratio, 1.44) and with lower risk of progression to cirrhosis (hazard ratio, 0.56) and incident HCC (hazard ratio, 0.51).

"Statin use was associated with improved rates to and decreased progression of and incidence of HCC among a large cohort of HCV positive Veterans," the authors write.

Several authors disclosed financial ties to the pharmaceutical and biotechnology industries.


Explore further

Life expectancy among patients with chronic hepatitis C virus infection and cirrhosis

More information: Abstract
Full Text (subscription or payment may be required)
Journal information: Hepatology

Copyright © 2015 HealthDay. All rights reserved.

Citation: Statin use found beneficial in hepatitis C treatment (2015, April 10) retrieved 15 November 2019 from https://medicalxpress.com/news/2015-04-statin-beneficial-hepatitis-treatment.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
63 shares

Feedback to editors

User comments